DK2739293T3 - Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus - Google Patents
Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus Download PDFInfo
- Publication number
- DK2739293T3 DK2739293T3 DK12746243.0T DK12746243T DK2739293T3 DK 2739293 T3 DK2739293 T3 DK 2739293T3 DK 12746243 T DK12746243 T DK 12746243T DK 2739293 T3 DK2739293 T3 DK 2739293T3
- Authority
- DK
- Denmark
- Prior art keywords
- vaccinavirus
- compositions
- production
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515724P | 2011-08-05 | 2011-08-05 | |
| PCT/US2012/049550 WO2013022764A1 (en) | 2011-08-05 | 2012-08-03 | Methods and compositions for production of vaccina virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2739293T3 true DK2739293T3 (da) | 2020-08-24 |
Family
ID=46650950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12746243.0T DK2739293T3 (da) | 2011-08-05 | 2012-08-03 | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9719105B2 (enExample) |
| EP (1) | EP2739293B1 (enExample) |
| JP (1) | JP6243333B2 (enExample) |
| KR (1) | KR102022952B1 (enExample) |
| CN (1) | CN103732236B (enExample) |
| AU (1) | AU2012294606B2 (enExample) |
| BR (1) | BR112014000787B1 (enExample) |
| CA (1) | CA2841831C (enExample) |
| DK (1) | DK2739293T3 (enExample) |
| ES (1) | ES2813413T3 (enExample) |
| PL (1) | PL2739293T3 (enExample) |
| WO (1) | WO2013022764A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| WO2016128542A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CA2990133A1 (en) | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
| CN106676071B (zh) * | 2015-11-06 | 2019-07-19 | 天士力创世杰（天津）生物制药有限公司 | HeLa-F细胞及其用途 |
| EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| ES2905478T3 (es) | 2016-12-28 | 2022-04-08 | Transgene Sa | Virus oncolíticos y moléculas terapéuticas |
| JP7718815B2 (ja) | 2017-04-21 | 2025-08-05 | シルラゼン， インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法 |
| KR102684237B1 (ko) | 2017-06-21 | 2024-07-11 | 트랜스진 | 개인 맞춤형 백신 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CN113330111A (zh) * | 2018-11-21 | 2021-08-31 | 西方溶瘤细胞有限公司 | 病毒的制造 |
| IL284421B2 (en) | 2018-12-28 | 2025-05-01 | Transgene | M2-defective poxvirus |
| KR102228267B1 (ko) | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| CN112143693B (zh) * | 2019-06-28 | 2024-12-27 | 杭州康万达医药科技有限公司 | 一种生产病毒的方法及收获液组合物 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| CA3183701A1 (en) * | 2020-06-22 | 2021-12-30 | Sung Jin Kim | Method for large scale-production of vaccinia virus using suspension cells |
| TW202217002A (zh) | 2020-07-13 | 2022-05-01 | 法商傳斯堅公司 | 免疫抑制之治療 |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| WO2022232375A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| CN114395538A (zh) * | 2022-01-19 | 2022-04-26 | 和元生物技术（上海）股份有限公司 | 一种促进重组病毒载体向细胞外分泌的方法 |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| CN120380015A (zh) | 2022-08-18 | 2025-07-25 | 特兰斯吉恩公司 | 嵌合痘病毒 |
| AU2024236322A1 (en) * | 2023-03-10 | 2025-08-21 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| DE20122302U1 (de) * | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| AU2003258168B2 (en) | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| DK1869171T4 (en) * | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| JP5326155B2 (ja) * | 2006-08-07 | 2013-10-30 | 一般財団法人化学及血清療法研究所 | 痘瘡生ワクチンの製造方法 |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| JP2013500717A (ja) | 2009-07-28 | 2013-01-10 | コーニング インコーポレイテッド | 細胞を培養するための合成マイクロキャリア |
| EP2477499B1 (en) * | 2009-09-14 | 2018-04-11 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
-
2012
- 2012-08-03 JP JP2014524110A patent/JP6243333B2/ja active Active
- 2012-08-03 AU AU2012294606A patent/AU2012294606B2/en active Active
- 2012-08-03 BR BR112014000787-0A patent/BR112014000787B1/pt active IP Right Grant
- 2012-08-03 WO PCT/US2012/049550 patent/WO2013022764A1/en not_active Ceased
- 2012-08-03 ES ES12746243T patent/ES2813413T3/es active Active
- 2012-08-03 KR KR1020147005901A patent/KR102022952B1/ko active Active
- 2012-08-03 DK DK12746243.0T patent/DK2739293T3/da active
- 2012-08-03 CA CA2841831A patent/CA2841831C/en active Active
- 2012-08-03 CN CN201280038029.8A patent/CN103732236B/zh active Active
- 2012-08-03 EP EP12746243.0A patent/EP2739293B1/en active Active
- 2012-08-03 PL PL12746243T patent/PL2739293T3/pl unknown
- 2012-08-03 US US14/236,982 patent/US9719105B2/en active Active
-
2017
- 2017-06-27 US US15/634,765 patent/US10202581B2/en active Active
-
2019
- 2019-02-07 US US16/270,585 patent/US10767166B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014000787B1 (pt) | 2021-04-13 |
| US20140162342A1 (en) | 2014-06-12 |
| JP2014521353A (ja) | 2014-08-28 |
| CA2841831C (en) | 2019-12-31 |
| CN103732236A (zh) | 2014-04-16 |
| US10202581B2 (en) | 2019-02-12 |
| CA2841831A1 (en) | 2013-02-14 |
| EP2739293B1 (en) | 2020-06-10 |
| US10767166B2 (en) | 2020-09-08 |
| US9719105B2 (en) | 2017-08-01 |
| EP2739293A1 (en) | 2014-06-11 |
| KR102022952B1 (ko) | 2019-09-20 |
| US20190169578A1 (en) | 2019-06-06 |
| AU2012294606A1 (en) | 2014-01-23 |
| PL2739293T3 (pl) | 2020-11-16 |
| KR20140058601A (ko) | 2014-05-14 |
| AU2012294606B2 (en) | 2016-10-06 |
| BR112014000787A2 (pt) | 2017-07-11 |
| ES2813413T3 (es) | 2021-03-23 |
| CN103732236B (zh) | 2017-09-15 |
| US20170298324A1 (en) | 2017-10-19 |
| WO2013022764A1 (en) | 2013-02-14 |
| JP6243333B2 (ja) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| DK2872153T3 (da) | Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK3702443T3 (da) | Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller | |
| DK2533761T3 (da) | Fremgangsmåder og sammensætninger til fremstilling af aerosoler | |
| DK2718404T3 (da) | Fremgangsmåde til fremstilling af flydende carbonhydrider | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK3421051T3 (da) | Fremgangsmåder til glycokonjugering og sammensætninger | |
| DK2736837T3 (da) | Fremgangsmåde til fremstilling af nanosiliciumtråde | |
| LT2791160T (lt) | Modifikuotos mrnr sudėtys | |
| DK3366143T3 (da) | Probiotiske sammensætninger og fremgangsmåder | |
| DK4082530T3 (da) | Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme | |
| HRP20181818T1 (hr) | Postupak za proizvodnju supstituiranih 5-fluoro-1h-pirazolopiridina | |
| DK2758349T3 (da) | Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf | |
| BR112014010450A2 (pt) | composição e método | |
| DK3141548T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af azaindoler | |
| DK3077513T5 (da) | Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf | |
| DK3210978T3 (da) | Fremgangsmåde til fremstilling af acesulfamkalium | |
| DK2785801T4 (da) | Fremgangsmåde til formindskelse af isdannelse på et underlag | |
| DK3299356T3 (da) | Fremgangsmåde til fremstilling af pleuromutiliner | |
| DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
| DK2627656T3 (da) | Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf |